NCT04535167View on ClinicalTrials.gov

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 9, 2020

Primary Completion Date

June 7, 2021

Study Completion Date

June 7, 2021

Conditions
Viral Disease
Interventions
DRUG

PF-07304814

PF-07304814 is an anti-viral, formulated for intravenous delivery

DRUG

Placebo

Placebo will be formulated for intravenous delivery

Trial Locations (13)

1020

University Hospital Brugmann, Brussels

28040

Hospital Universitario Fundacion Jimenez Diaz, Madrid

38103

Regional One Health, Memphis

41013

Hospital Universitario Virgen Del Rocio, Seville

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

94040

El Camino Health, Mountain View

Palo Alto Medical Foundation, Mountain View

95817

UC Davis Health Investigational Drug Pharmacy, Sacramento

UC Davis Medical Center, Sacramento

30150221

Santa Casa De Misericórdia de Belo Horizonte, Belo Horizonte

02114

Massachusetts General Hospital Translational and Clinical Research Center, Boston

Massachusetts General Hospital, Clinical Trials Pharmacy, Boston

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04535167 - First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19. | Biotech Hunter | Biotech Hunter